PMID: 8595536Feb 1, 1996Paper

Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
F LeynadierP Attali

Abstract

Mizolastine is a new, nonsedating antihistamine under clinical investigation for treatment of allergic rhinitis and urticaria. The purpose of this study was to determine the optimally active dose of once-daily mizolastine in seasonal allergic rhinitis. This multicenter, double-blind, parallel study involved 494 patients randomly allocated to mizolastine (5, 10, or 15 mg) or placebo for 2 weeks. Physicians' assessments indicated the superiority of 10 and 15 mg mizolastine to placebo in reducing total symptom scores (P=.002), nasal scores (P=.004), and ocular scores (P=.007) at day 7. Patients' diaries showed a significant change from baseline in daily symptom scores as early as day 2 (P=.01) in 10- and 15-mg mizolastine groups in comparison to placebo, but this was not maintained throughout the study. No additional benefits were demonstrated during the second week of treatment in terms of efficacy. Adverse events were slightly more frequent in the 15-mg mizolastine group. This study conforms mizolastine is an effective and well tolerated antihistamine in the treatment of seasonal allergic rhinitis; 10 mg is the optimal dose.

Citations

Mar 15, 2002·Current Allergy and Asthma Reports·M Okuda, UNKNOWN US Food and Drug Administration (FDA)
Sep 25, 2002·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Charles FrèchePaul Ben Soussen
Aug 3, 2000·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·L MichelL Dubertret
Oct 29, 1999·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·A SabbahP Attali
Apr 9, 2001·Allergy·F M Baroody, R M Naclerio
Nov 18, 2000·British Journal of Pharmacology·M TaglialatelaL Annunziato
Mar 5, 2002·British Journal of Clinical Pharmacology·A PurohitN Frossard
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·D Reichmuth, R F Lockey
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·P Rosenzweig, A Patat
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M C Delauche-CavallierA Wajman
Feb 20, 2008·Immunology and Allergy Clinics of North America·Leonard Bielory
Feb 28, 2004·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M TriggianiG Marone
Feb 7, 2002·Expert Opinion on Investigational Drugs·Luis M Salmun
Oct 11, 2005·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·John H KrouseDarrell Hunsaker
Jul 10, 1999·The Journal of International Medical Research·M SternM S Judd
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Lars P Nielsen, Ronald Dahl
May 21, 1999·British Journal of Clinical Pharmacology·S ChaufourP Rosenzweig
Nov 15, 2001·The Journal of Allergy and Clinical Immunology·J BousquetUNKNOWN World Health Organization

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.